US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter

FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

FDA Approved Sun Pharma's Leqselvi (deuruxolitinib) for Severe Alopecia Areata

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

FDA Drug Approvals | 2024 | iPharmaCenter

FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter

FDA Gives Green Light to First Medication for Individuals with Liver Scarring Stemming from Fatty Liver Condition | iPharmaCenter

2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter

FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter

Chikungunya | Drugs | Vaccines | News | Updates | iPharmaCenter

Project Orbis News | Updates | Truqap approved in the US

FDA-Approved Chronic Weight Management Drug Zepbound, rival to Wegovy

UCB potential multi-billion blockbuster Bimzelx approved for plaque psoriasis | FDA | iPharmaCenter

Pfizer's Abrysvo approved in US to prevent RSV infection in infants |iPharmaCenter

Pfizer's Elrexfio approved for heavily pretreated multiple myeloma patients | iPharmaCenter

FDA gave nod for Zurzuvae to treat postpartum depression but NO to major depressive disorder

FDA Approved RSV treatments | iPharmaCneter

BioMarin Pharmaceutical's $2.9 million gene therapy Roctavian was approved for haemophilia A

FDA Approved diabetic treatments | 2023 |

FDA Approved Myasthenia gravis treatments | News | Updates | iPharmaCenter

US FDA approved drugs for Duchenne Muscular Dystrophy | Elevidys | Viltepso | iPharmaCenter

FDA News and Updates | US Pharma News | iPharmaCenter

2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

Gilead’s Trodelvy approved for triple-negative breast cancer in US

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC